Science
Targeting inflammation signalling inside the cell
Carocell Bio’s approach combines peptide inhibitors of p38α MAP kinase with nanoparticle delivery. The aim is to investigate how modulation of inflammatory signalling could support future therapies.
01
The p38α MAPK target
In the company’s description, external triggers such as lipopolysaccharide (LPS) or UV activate a kinase cascade (MAPKKK → MAPKK → p38α) that drives the release of inflammatory cytokines including IL-1β, IL-6 and TNF-α.
The diagram below, published by the company, also shows a feedback loop in which released cytokines can re-activate the cascade. Carocell Bio’s peptides are designed to inhibit p38α activation within this cascade.
02
Nanoparticle delivery for the skin
The company combines its peptides with nanoparticle delivery, with the objective of topical formulations — a cream is described for JEL0305 and a sterile spray concept for JEL3108 in skin-injury contexts.
No skin-penetration percentages or delivery performance data are presented in the reviewed sources, and none are shown here.
03
Company-reported cellular findings
The research page presents dose-response data in which cells stimulated with LPS were exposed to different peptide concentrations, with an inflammation index measured as TNF-α.
These are in vitro results reported by the company. They indicate a research direction, not a clinical effect.
How to read this evidence
Cellular and ex vivo tissue studies are preclinical. They can inform whether a programme continues, but they cannot establish that a treatment works or is safe in people.